- Home
- TLSA vs MIST Comparison
TLSA vs MIST Comparison
Compare TLSA & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- MIST
- Stock Information
- Founded
- TLSA 2013
- MIST 2003
- Country
- TLSA United Kingdom
- MIST Canada
- Employees
- TLSA N/A
- MIST N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- MIST Health Care
- Exchange
- TLSA Nasdaq
- MIST Nasdaq
- Market Cap
- TLSA 87.8M
- MIST 81.5M
- IPO Year
- TLSA 2000
- MIST N/A
- Fundamental
- Price
- TLSA $1.20
- MIST $1.43
- Analyst Decision
- TLSA
- MIST Strong Buy
- Analyst Count
- TLSA 0
- MIST 3
- Target Price
- TLSA N/A
- MIST $13.00
- AVG Volume (30 Days)
- TLSA 145.8K
- MIST 177.8K
- Earning Date
- TLSA 05-10-2024
- MIST 11-11-2024
- Dividend Yield
- TLSA N/A
- MIST N/A
- EPS Growth
- TLSA N/A
- MIST N/A
- EPS
- TLSA N/A
- MIST N/A
- Revenue
- TLSA N/A
- MIST N/A
- Revenue This Year
- TLSA N/A
- MIST N/A
- Revenue Next Year
- TLSA N/A
- MIST N/A
- P/E Ratio
- TLSA N/A
- MIST N/A
- Revenue Growth
- TLSA N/A
- MIST N/A
- 52 Week Low
- TLSA $0.41
- MIST $1.12
- 52 Week High
- TLSA $1.74
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- TLSA 65.44
- MIST 42.50
- Support Level
- TLSA $0.83
- MIST $1.41
- Resistance Level
- TLSA $0.92
- MIST $1.53
- Average True Range (ATR)
- TLSA 0.09
- MIST 0.07
- MACD
- TLSA 0.03
- MIST -0.01
- Stochastic Oscillator
- TLSA 84.52
- MIST 26.96
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).